CALGARY, AB, June 17, 2026 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (NASDAQ: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that its majority-owned subsidiary, Remexian Pharma GmbH ("Remexian"), showcased its exclusive German medical cannabis distribution partnerships with leading Canadian cannabis brands at Mary Jane Berlin 2026, one of Europe's largest cannabis trade shows, held June 11–14, 2026, in Berlin, Germany. Through these partnerships, Remexian is bringing premium Canadian medical cannabis products to German patients and pharmacies, further strengthening its position as a leading importer and distributor in one of the world's fastest-growing medical cannabis markets.
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
High Tide's German Subsidiary Remexian Pharma Showcases Exclusive Canadian Medical Cannabis Brand Partnerships at Mary Jane Berlin 2026
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
